Currently, in the minimally invasive treatment of cerebral hemorrhage
surgery, the most commonly used fibrinolytic drugs are tissue plasminogen
activator (tPA), which can make the formation of blood clots in the brain
quickly ablation, so that doctors can clean up as soon as possible. However, it
is expensive, which not only brings great economic pressure to patients, but
also proves that tPA may cause delayed brain edema and nerve injury.
Urokinase project research, 973, head of the plan's chief scientist,
southwest hospital neurosurgery team Feng Hua professor and his team in an
academic exchange and data access accidental discovery, a few small hospital and
clinical research center had in minimally invasive surgery joint fibrinolytic
eliminate using urokinase records in the cerebral hemorrhage, but the lack of
relevant data to support. According to professor feng hua, urokinase plasminogen
activator (uPA), as a common drug, has been used for many years in China, mainly
for thrombolytic therapy of thromboembolic diseases, including acute extensive
pulmonary embolism and myocardial infarction, but it has not been used as a
major fibrinolytic drug in minimally invasive surgery.
The team realized that urokinase might better focus on how to reduce the
volume of intracerebral hematoma in minimally invasive surgery and protect the
neural tissue in the brain. According to this idea, professor feng hua and his
team have conducted more than two years of specific research.
"In this study, we used the classic 'intracerebral autologous blood
injection' to simulate human intracerebral hemorrhage, and used uPA and tPA as
minimally invasive fibrinolytic agents to remove intracerebral hematomas,
respectively." Professor feng hua said.
The results showed that uPA and tPA injection both effectively reduced the
volume of intracerebral hematoma, but uPA better reduced the cerebral edema
around the hematoma, and protected the blood-brain barrier tight junction
protein and intracerebral nerve function, thereby improving the success rate of
Feng hua said that his research team will conduct large animal models and
clinical trials to further verify the safety and effectiveness of uPA in the
treatment of cerebral hemorrhage, and the findings are expected to provide new
ideas and methods for neurosurgeons to treat cerebral hemorrhage and other